Clinical Trial: CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519187) titled 'CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms' on April 02.

Brief Summary: This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Study Start Date: April 03

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Plasma Cell Neoplasms

Intervention: GENETIC: CAR 70-BCMA CAR-T

Each subject will receive a single infusion of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation design will be employed.

DRUG: Fludarabine and Cyclophosphamide

Drug: Fludarabine Fludarabine will ...